PGD2/DP2 receptor activation promotes severe viral bronchiolitis by suppressing IFN- λ production
- 9 May 2018
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (440)
Abstract
RSV-induced prostaglandin D2 release contributes to disease severity by impairing IFN-λ production.Keywords
Funding Information
- Australian Infectious Disease Research Excellence Award
- NHRMRC Development grant
- Australian Research Council Future Fellowship
This publication has 64 references indexed in Scilit:
- Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host FitnessImmunity, 2017
- Risk of childhood asthma following infant bronchiolitis during the respiratory syncytial virus seasonJournal of Allergy and Clinical Immunology, 2013
- Prostaglandin D2 pathway upregulation: Relation to asthma severity, control, and TH2 inflammationJournal of Allergy and Clinical Immunology, 2013
- Increased airway smooth muscle in preschool wheezers who have asthma at school ageJournal of Allergy and Clinical Immunology, 2013
- Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patientsJournal of Allergy and Clinical Immunology, 2013
- Deficient antiviral immune responses in childhood: Distinct roles of atopy and asthmaJournal of Allergy and Clinical Immunology, 2012
- Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammationEuropean Journal of Pharmacology, 2010
- Toward improved prediction of risk for atopy and asthma among preschoolers: A prospective cohort studyJournal of Allergy and Clinical Immunology, 2010
- In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjectsJournal of Allergy and Clinical Immunology, 2009
- PGD2 metabolism in plasma: Kinetics and relationship with bioactivity on DP1 and CRTH2 receptorsBiochemical Pharmacology, 2007